FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies, related to HIV-associated lipodystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Lipodystrophy

Drugs mentioned

• EGRIFTA WR (TESAMORELIN)

Snippet

SUPPL AP for EGRIFTA WR (TESAMORELIN)